title: Hypolipidaemic effects of fenofibrate are not altered by mildronate-mediated normalization of carnitine concentration in rat liver.
abstract: The five-fold higher carnitine content in the liver of fenofibrate-treated rats addresses the question about the possible role of this enhancement in the hypolipidaemic effect of the drug and the underlying mechanisms. When fenofibrate was administered with mildronate (a gamma-butyrobetaine hydroxylase inhibitor) in suitable amount, the content in carnitine was found to be normalized in liver. However, triglyceride contents of liver and serum were then at least as low as in rats treated by fenofibrate only. When carnitine concentration was lowered by mildronate to the third of the normal value, a marked increase in triglycerides occurred both in liver and serum, while the five-fold increase in carnitine due to fenofibrate enhanced blood ketone body concentration with no effect on liver and serum triglycerides. Data suggest that the normal carnitine concentration is largely sufficient to meet the usual requirement for carnitine palmitoyltransferase I activity (CPT I). In rat liver, increase in mitochondrial CPT I activity and in peroxisomal fatty acid oxidation may constitute part of the hypolipidaemic effect of fenofibrate.
authors.affiliation: Laboratoire de Nutrition Cellulaire et Métabolique, UPRES 2422, Université de Bourgogne, Faculté des Sciences, Dijon, France.
authors.forename: M
authors.initials: M
authors.lastname: Tsoko
authors.forename: F
authors.initials: F
authors.lastname: Beauseigneur
authors.forename: J
authors.initials: J
authors.lastname: Gresti
authors.forename: J
authors.initials: J
authors.lastname: Demarquoy
authors.forename: P
authors.initials: P
authors.lastname: Clouet
mesh_terms: D000818:Animals; D002331:Carnitine / Q000097:blood / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D011345:Fenofibrate / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007657:Ketone Bodies / Q000097:blood / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008297:Male; D008763:Methylhydrazines / Q000494:pharmacology*; D018482:Muscle, Skeletal / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D010743:Phospholipids / Q000097:blood / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000378:metabolism
chemical_list: D000960:Hypolipidemic Agents; D007657:Ketone Bodies; D008763:Methylhydrazines; D010743:Phospholipids; D014280:Triglycerides; C050147:3-(2,2,2-trimethylhydrazine)propionate; D002784:Cholesterol; D002331:Carnitine; D011345:Fenofibrate